Is Aphria (APHA) a Buy Under $3?

NYSE:MJ March 9, 2020 1:31pm

3 Reasons Why You Should Avoid Tilray (TLRY)

NYSE:MJ February 21, 2020 2:27pm

What Sundial’s (SNDL) Executive Shake Up Could Mean for This Stock

NYSE:MJ January 31, 2020 2:09pm

Will Shares of HEXO Sink or Swim in 2020?

Now that 2019 is behind us we're beginning to see a breakout among the pack of publicly traded cannabis companies, and Hexo (HEXO) stock seems like it could go any direction. One of the main concerns some investors have is that HEXO is not as insulated from the woes of the Canadian recreational market as some of its competitors. While many of the Hexo's publicly traded peers have operations in other countries, operations in medical markets, and/or generate revenue via ancillary cannabis operations (such as Real Estate Investment Trusts), Hexo seems to have gone all in on Canada's Rec 2.0 with their commitment to the derivatives and edibles markets, and its partnership with Molson Coors (TAP). For the most part, HEXO's challenges have been uniquely Canadian. While no cannabis stock was immune from the market spike and crash of 2019, Hexo's situation is being compounded by a bottlenecked Canadian retail market. Legal edibles, beverages, derivatives and vapes are finally beginning to hit the shelves in Canada this month. But questions remain: How big of a piece is HEXO going to get from that, and how soon? If Canada's brief history of the legal market is any indicator (and history often isn't), the rollout of Rec 2.0 could be slower-than-expected and yield lackluster results. There's no question that consumer demand is there. The Canadian Market by Numbers In calendar Q1 2018, 4.18 million Canadians ages 15 and older used cannabis. By Q3 2019, that number expanded to nearly 5.2 million. Meanwhile, HEXO's year-over-year growth rate in the trailing three quarters dropped from 27% to 14%. There is a disconnect somewhere, and by most accounts it begins with the Canadian government's perplexing rollout strategy for cannabis retail stores.  For example, between Q1 2018 through Q3 2019 Ontario accounted for nearly 41% of the Canadian cannabis market share. But as of October 2019, the province only had 75 cannabis stores that were approved (or scheduled to be) and open for business. Considering this province has more than 2 million cannabis users, that breaks down 26,972 users per store. Comparatively, British Columbia has 830,000 cannabis users but only 104 stores, which equals less than 8,000 users per store. And the city of Calgary currently has 200 stores per its 1.34 million residents. Assuming that 17% of them are marijuana users, that figure equates to 1,139 stores per user. Much of Hexo's success is pending on how soon the Canadian government can loosen the reins on this hodgepodge retail strategy.   HEXO stock kicked off the first trading day of 2020 nearly 16% below its $1.96 closing price of Dec. 24. On top of that, Hexo stock is down more than 80% since the beginning of May 2019, leaving many investors to wonder if it's finally hit bottom. And just last week the company closed its registered direct offering, under which the Hexo sold 15 million common shares at $1.67 per share, for gross proceeds of $25 million. It also issued 5-year warrants to purchase approximately 7.5 million shares at $2.45. But these are the types of moves that have investors growing weary on the cannabis industry. While nearly all of Hexo's peers have resorted to raising cash through equity offerings, investors usually would rather not see companies pursue dilutive measures to continue their growth strategies.
HEXO Corp. (HEXO) was trading at $1.45 per share on Thursday afternoon, up $0.06 (+4.32%). Year-to-date, HEXO has declined N/A%, versus a 22.87% rise in the benchmark S&P 500 index during the same period.

About the Author: Eric Bowler

eric-bowlerEric Bowler is an accomplished journalist providing in-depth insights for more than two decades. Over the past several years his focus has been on the marijuana industry, with a special interest in cannabis growth stocks. His daily coverage of the industry keeps him on top of the key trends with the goal of helping investors make well-informed decisions.
NYSE:MJ January 9, 2020 12:23pm

Why are Shares of Aphria (APHA) up 30% in the past month?

NYSE:MJ December 23, 2019 11:28am

Canopy Growth (CGC) is Making Headlines This Week, What Does it Mean for the Stock?

NYSE:MJ December 19, 2019 2:26pm

What Innovative Industrial Properties’ (IIPR) New Dividends Could Mean for this Stock

NYSE:MJ December 10, 2019 4:55pm

What Caused Today’s Rally in Cannabis Stocks?

NYSE:MJ December 9, 2019 5:41pm

What Aphria’s (APHA) $80 million Financing Could Mean for This Stock

NYSE:MJ December 5, 2019 11:20am

What Does Aurora Cannabis’ CBD Approval Mean for the Stock?                   

NYSE:MJ December 3, 2019 4:52pm

Why Did the Cannabis ETF MJ Rally 10% Yesterday?

NYSE:MJ November 22, 2019 12:50pm

Is Cronos Group (CRON) a Buy After Yesterday’s Earnings?

NYSE:MJ November 13, 2019 3:10pm

Is GW Pharmaceuticals (GWPH) a Buy Before it Reports Earnings?

Earlier this week, an H.C. Wainwright analyst initiated coverage of GW Pharmaceuticals (GWPH), adding to the buzz already surrounding this increasingly popular cannabis stock. On Wednesday, H.C. Wainwright analyst Douglas Tsao initiated coverage, giving the stock a "Buy" rating and $170 price target. In a note to investors, Tsao said that he expects GWPH stock to move higher as its quarterly results demonstrate that Epidiolex's launch is sustainable. Additionally, he believes that dose titration and penetration into off-label patient populations "should fuel growth and offer a bridge" to the anticipated label expansion into the tuberous sclerosis complex by mid-2020. In GW Pharmaceuticals' most recent earnings release, the company surprised investors by posting a positive earnings of 64.9%. GWPH has exceeded industry expectations in each of the most recent four quarters, with an average positive earnings of 26.7%. GWPH stock has increased 20.94% in the past month, which has outpaced both the Medical sector's gain of 3.22% and the S&P 500's gain of 2.66%, during the same period. How GWPH got to where it is now GW Pharmaceuticals first commercially launched Epidolex in the United States last November. Epidolex is the first cannabis-derived drug for patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome. And while GWPH was not immune to the boom and bust cycle that ravaged cannabis stocks between the spring and fall of this year, GW Pharmaceuticals seems to be rebounding nicely compared to its industry peers. Throughout the past few months, the company has experienced an increase in receptiveness and demand for Epidolex in the United States, as more and more physicians are recommending the drug in their prescriptions.  Investors anticipate a growing level of market penetration from the third quarter as well. They attribute this to market research conducted on Epidiolex during the second quarter, which seemed to drive awareness for LGS and Dravet, meaning that Epidiolex's third quarter sales are likely to have gained courtesy of more prescriptions.  GW Pharmaceuticals' focus has been on making Epidiolex a leading brand for epilepsy treatment. Adding to the company's success in this regard, the European Commission recently approved the marketing authorization of Epidiolex for patients aged 2 years and older. This too, is anticipated to help the company's third quarter results. As far as coverage determination is concerned, GWPH has been increasing payor access for some time now. Investors anticipate that this will also continue in the third quarter. Many investors anticipate that GW Pharmaceuticals' Q3 earnings should reflect the expansion of the Epidiolex label to TSC on a favorable outcome of Phase 3 trial data for Epidiolex, and the treatment of seizures associated with tuberous sclerosis complex. Another one of GWPH's cannabis-derived drugs that's been rising in popularity is Sativex, which is used to treat muscle spasms. Expect a reflection on this drug's performance in the upcoming earnings report. GW Pharmaceuticals also has a CBDV program that's been performing well. One can expect more news on this in the upcoming report. Keep an eye out for the Q3 earnings release due next week on November 5, 2019.
GW Pharmaceuticals PLC ADR (GWPH) was unchanged in after-hours trading Friday. Year-to-date, GWPH has declined N/A%, versus a 15.18% rise in the benchmark S&P 500 index during the same period.

About the Author: Eric Bowler

eric-bowlerEric Bowler is an accomplished journalist providing in-depth insights for more than two decades. Over the past several years his focus has been on the marijuana industry, with a special interest in cannabis growth stocks. His daily coverage of the industry keeps him on top of the key trends with the goal of helping investors make well-informed decisions.
NYSE:MJ November 1, 2019 5:49pm

Get Free Updates

Join over 50,000 investors who get the latest news from ETFDailyNews.com!

Most Popular


From Our Partners


Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories